单细胞图谱揭示多发性骨髓瘤免疫微环境中巨噬细胞重编程及潜在的双重巨噬细胞靶向策略
本研究通过单细胞RNA测序描绘多发性骨髓瘤不同疾病阶段的肿瘤微环境图谱,发现疾病进展过程中自然杀伤细胞和CD8+ T细胞耗竭、巨噬细胞重编程为混合M1/M2表型且吞噬功能受损。细胞相互作用分析鉴定出SIRPA-CD47和CD74-MIF两条配体-受体对,CD47和MIF表达与疾病进展及不良结局相关。作者设计抗CD47抗体联合MIF抑制剂的双重巨噬细胞靶向策略,并在体外和体内实验中证明其抗肿瘤效应。
要点
- 疾病进展期骨髓瘤微环境呈自然杀伤细胞和CD8+ T细胞耗竭及巨噬细胞重编程。
- 重编程肿瘤相关巨噬细胞呈混合M1/M2表型且吞噬功能受损,两个巨噬细胞亚群仅见于骨髓瘤阶段且M2评分较高。
- 抗CD47抗体联合MIF抑制剂的双重巨噬细胞靶向策略在体外和体内均显示抗肿瘤效应。
核心结论
- 研究描绘了多发性骨髓瘤疾病进展过程中肿瘤微环境的改变并揭示了肿瘤相关巨噬细胞的重编程。
- 同时阻断CD47和MIF的双重巨噬细胞靶向策略显示出抗肿瘤效应。
研究设计与样本
- 对来自不同疾病阶段的样本进行单细胞RNA测序。
- 通过bulk RNA测序、流式细胞术及体外和体内功能实验验证发现。
主要发现
- 疾病进展过程中肿瘤微环境呈现自然杀伤细胞和CD8+ T细胞耗竭富集及巨噬细胞重编程。
- 重编程的肿瘤相关巨噬细胞显示混合M1/M2表型,两个仅见于骨髓瘤阶段的肿瘤相关巨噬细胞亚群M2评分较高。
- 在临床队列中验证了肿瘤相关巨噬细胞的混合M1/M2表型并证实重编程肿瘤相关巨噬细胞吞噬功能受损。
- 细胞相互作用分析鉴定出巨噬细胞与恶性浆细胞之间富集的两对配体-受体对:抑制吞噬的SIRPA-CD47通路和重塑巨噬细胞表型的CD74-MIF通路。
- CD47和MIF的表达与疾病进展及不良结局相关。
临床怎么用
- 作者设计了联合抗CD47抗体和MIF抑制剂的双重巨噬细胞靶向策略,以激活吞噬作用并将巨噬细胞复极化为功能表型,并在体外和体内实验中证明了其抗肿瘤效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The tumour microenvironment (TME) plays a critical role in disease progression in multiple myeloma (MM). This study aimed to present an atlas of MM-TME in disease progression and explore TME-directed therapeutic strategies. We performed single-cell RNA sequencing (scRNAseq) in samples from different disease stages. We validated the findings by bulk RNAseq, flow cytometry (FCM) and in vitro and in vivo functional experiments. We delineated a compromised TME during disease progression, characterized by enrichment of exhausted NK cells and CD8+ T cells and reprogramming of macrophages (MPs). The reprogrammed tumour-associated MPs (TAMs) displayed a mixed phenotype showing both M1 and M2 features, with two TAM clusters exclusively present in the MM stage showing higher M2 scores. We validated the mixed M1/M2 phenotype in TAMs in a clinical cohort and verified phagocytic dysfunction in reprogrammed TAMs. Cellular interaction analysis identified two enriched ligand-receptor pairs between MPs and malignant plasma cells (PCs), including the SIRPA-CD47 pathway suppressing phagocytosis and the CD74-MIF (macrophage inhibitory factor) reshaping the phenotype of MPs. The expression of CD47 and MIF correlated with disease progression and adverse outcomes. We designed a dual-MP-targeted strategy by combining an anti-CD47 antibody and MIF inhibitor to activate phagocytosis and repolarize MP to a functional phenotype and proved its potent antitumour effect in vitro and in vivo. We drafted alterations in MM-TME during disease progression and unravelled TAM's reprogramming. The dual MP-targeted approach blocking both CD47 and MIF showed potent antitumour effects.
引用
- Li J, Yang Y, Wang W, et al. Single-cell atlas of the immune microenvironment reveals macrophage reprogramming and the potential dual macrophage-targeted strategy in multiple myeloma. Br J Haematol. 2023. PMID: 36852636. doi:10.1111/bjh.18708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。